StockDuty ← Dashboard Oct 28, 2026 11:56 AM ET
SignalGeopolitics

Regeneron Earnings Preview: Dupixent Is Booming, But It's Still Overvalued

Dupixent growth highlighted ahead of earnings, but valuation concerns temper the score.

What happened: Regeneron Pharmaceuticals ($REGN) Q3 earnings are due October 30th, with another solid Dupixent contribution expected. The stock is rated Sell at $808. Key numbers: Fair value ~$675, implying 16.4% downside risk. Dupixent patent expiration in 2031. Why it matters: Dupixent growth is strong, but patent expiration and biosimilar risks cap long-term upside reflected in today's price. EYLEA HD gains are offset by legacy product declines, making slower franchise erosion critical for cash flow.
Regeneron Pharmaceuticals ($REGN) Q3 earnings are due October 30th, with another solid Dupixent contribution expected. The stock is rated Sell at $808.
Dupixent growth is strong, but patent expiration and biosimilar risks cap long-term upside reflected in today's price. EYLEA HD gains are offset by legacy product declines, making slower franchise erosion critical for cash flow.
Sources